Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma.

Autor: Einerhand SMH; Department of Surgical Oncology (Urology), Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dorp J; Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Molecular Carcinogenesis, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Molecular Carcinogenesis, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. Electronic address: basvanrhijn@hotmail.com.
Jazyk: angličtina
Zdroj: European urology [Eur Urol] 2023 Jan; Vol. 83 (1), pp. 91-92. Date of Electronic Publication: 2022 Oct 07.
DOI: 10.1016/j.eururo.2022.09.024
Databáze: MEDLINE
Externí odkaz: